

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

**DIS-APPLICATION OF RULES 18A.09 TO 18A.11
OF THE LISTING RULES**

CanSino Biologics Inc. (the “**Company**”) is pleased to announce that following an application to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), the Stock Exchange has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules (the “**Relevant Rules**”) to the Company.

As a result of the dis-application of the Relevant Rules, the “B” marker will no longer be affixed to the Company’s stock short name. The Company will make a further announcement in relation to the effective date of the removal of the “B” marker in due course.

REASONS FOR THE DIS-APPLICATION OF THE RELEVANT RULES

The Company is a biotechnology company which listed its H shares (the “**H Shares**”) on the Main Board of the Stock Exchange on March 28, 2019 pursuant to Chapter 18A of the Listing Rules.

The Company now satisfies the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules. In particular, the Company has a trading record of at least three financial years, management continuity for at least the three preceding financial years and ownership continuity and control for at least the most recent audited financial year. The Company’s market capitalization as of May 23, 2022 was over HK\$30.46 billion, which is well in excess of HK\$4 billion as required under Rule 8.05(3) of the Listing Rules. The Company’s revenue for the year ended December 31, 2021, being the most recent audited financial year of the Company, was RMB4,299.7 million (equivalent to approximately HK\$5,054.7 million), which is in excess of HK\$500 million as required under Rule 8.05(3) of the Listing Rules. Accordingly, the Company qualifies for listing under Rule 8.05(3) of the Listing Rules and the Stock Exchange has therefore granted its approval for the dis-application of the Relevant Rules to the Company.

EFFECTS OF THE DIS-APPLICATION OF THE RELEVANT RULES

The dis-application of the Relevant Rules will have no effect on the existing share certificates in respect of the Company’s H Shares which will continue to be good evidence of legal title and be valid for trading, settlement and registration purposes and will not involve any transfer or exchange of the existing share certificates for holders of H Shares. As a result of the dis-application of the Relevant Rules, the “B” marker will no longer be affixed to the Company’s stock short name. No other changes will be made to the English or Chinese stock short names of the Company, the existing share certificates, the board lot size, the trading currency of the H shares and the H share registrar and transfer offices of the Company following the dis-application of the Relevant Rules.

For the purpose of this announcement and for illustrative purpose only, conversions of RMB to HK\$ are based on the exchange rate published by the State Administration of Foreign Exchange on May 23, 2022, i.e. RMB85.063 = HK\$100. No representation is made that any amounts in HK\$ or RMB can be or could have been converted at the relevant dates at the above rate or at any other rates or at all.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 24, 2022

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.